多发性骨髓瘤治疗市场规模、份额、成长分析、按治疗类型、按给药途径、按疾病类型、按最终用途、按地区 - 行业预测，2025-2032

2023 年全球多发性骨髓瘤治疗市场规模价值 248 亿美元，预计将从 2024 年的 263.6 亿美元增长到 2032 年的 429.8 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.3%。

由于这种血液癌症的性质复杂，会损害骨髓并抑制浆细胞的产生，全球多发性骨髓瘤治疗市场正在经历显着增长。这种快速成长背后的主要因素是人口老化和对疾病分子机制的认识不断提高。干细胞移植、免疫调节药物、蛋白酶体抑制剂和单株抗体等专门而强效治疗方法的开发创新进展也推动了市场扩张。此外，製药公司正在大力投资研究，以生产尖端治疗方法和个人化医疗策略，进一步加剧了激烈的竞争。製药公司、生技公司和研究机构之间的合作推动了有效且副作用较少的治疗方法的推出，尤其是单株抗体和CAR-T细胞疗法，标誌着治疗选择的重要里程碑。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

多发性骨髓瘤治疗市场规模（依治疗类型）

• 市场概况
• 化疗
• 标靶治疗
• 免疫调节剂
• 干细胞移植
• 放射治疗
• 其他类型的治疗

多发性骨髓瘤治疗市场规模（依给药途径）

• 市场概况
• 口服
• 肠外

多发性骨髓瘤治疗市场规模（依疾病类型）

• 市场概况
• 活动性多发性骨髓瘤
• 冒烟型多发性骨髓瘤

多发性骨髓瘤治疗市场规模（依最终用途）

• 市场概况
• 医院
• 专科门诊
• 居家照护环境
• 其他最终用户

多发性骨髓瘤治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Bristol Myers Squibb（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Amgen Inc.（USA）
• Sanofi SA（France）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• GlaxoSmithKline plc（UK）
• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Celgene Corporation（USA）
• Karyopharm Therapeutics Inc.（USA）
• Ono Pharmaceutical Co., Ltd.（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Genmab A/S（Denmark）
• Adaptive Biotechnologies Corporation（USA）
• Legend Biotech Corporation（China）
• MorphoSys AG（Germany）
• bluebird bio, Inc.（USA）
• Secura Bio, Inc.（USA）
• BeiGene, Ltd.（China）

结论和建议

Global Multiple Myeloma Therapeutics Market size was valued at USD 24.8 billion in 2023 and is poised to grow from USD 26.36 billion in 2024 to USD 42.98 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).

The global multiple myeloma therapeutics market has experienced significant growth due to the complex nature of this hematological cancer, which damages bone marrow and disrupts plasma cell production. This surge is largely attributed to an aging population and heightened awareness of the disease's molecular mechanisms. Innovative advancements in the development of specialized and potent therapies, including stem cell transplants, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, have also fueled market expansion. Furthermore, pharmaceutical companies are heavily investing in research to create cutting-edge treatments and personalized care strategies, fostering a highly competitive landscape. Collaborations between pharma firms, biotech companies, and research institutions are driving the introduction of effective, low-side-effect therapies, notably monoclonal antibodies and CAR-T cell therapies, marking significant milestones in treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Myeloma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Myeloma Therapeutics Market Segmental Analysis

Global Multiple Myeloma Therapeutics Market is segmented by Treatment Type, Route of Administration, Disease Type, End-use and region. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted therapy, Immunomodulating agents, Stem cell transplantation, Radiation therapy and Other treatment types. Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on Disease Type, the market is segmented into Active multiple myeloma and Smoldering multiple myeloma. Based on End-use, the market is segmented into Hospitals, Specialty clinics, Homecare settings and Other end-users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Myeloma Therapeutics Market

One of the key drivers of the global Multiple Myeloma Therapeutics market is the significant advancements in treatment options. Recent discoveries in innovative therapies, including monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs (IMiDs), have proven to be highly beneficial. These cutting-edge medications are designed to specifically target cancer cells while minimizing harm to healthy cells, resulting in improved treatment efficacy. This progress has led to higher patient survival rates and enhanced quality of life following treatment. As researchers and pharmaceutical companies continue to develop these novel therapies, they further propel the growth and potential of the multiple myeloma therapeutics market.

Restraints in the Global Multiple Myeloma Therapeutics Market

The Global Multiple Myeloma Therapeutics market faces significant restraints, primarily due to the high costs associated with treatment options. Despite advancements that have enhanced patient outcomes through the introduction of various innovative therapies, the steep price tags attached to these treatments can create barriers for patients, particularly those in economically challenged regions or with limited access to healthcare services. This financial obstacle may discourage the adoption of state-of-the-art therapies, ultimately restricting the market's growth potential. Consequently, addressing affordability and accessibility is crucial to ensure that promising treatment options reach the patients who need them the most.

Market Trends of the Global Multiple Myeloma Therapeutics Market

The Global Multiple Myeloma Therapeutics market is witnessing a significant shift towards advancements in targeted therapies and immunotherapies, reflecting a broader trend of precision medicine in oncology. As traditional chemotherapy presents limitations in efficacy and adverse effects, pharmaceutical companies are increasingly investing in developing innovative treatments that specifically target malignant cells while preserving healthy tissues. This focus includes the creation of monoclonal antibodies and specialized agents designed to inhibit myeloma cell proliferation. Furthermore, cutting-edge immunotherapy approaches, such as CAR-T cell therapy, have demonstrated promising results in clinical trials, offering patients more personalized and effective treatment options, thus propelling market growth and investment in novel therapeutic modalities.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Multiple Myeloma Therapeutics Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Targeted therapy
• Immunomodulating agents
• Stem cell transplantation
• Radiation therapy
• Other treatment types

Global Multiple Myeloma Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral

Global Multiple Myeloma Therapeutics Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Active multiple myeloma
• Smoldering multiple myeloma

Global Multiple Myeloma Therapeutics Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty clinics
• Homecare settings
• Other end-users

Global Multiple Myeloma Therapeutics Market Size & CAGR (2025-2032)

• North America (Treatment Type, Route of Administration, Disease Type, End-use)
  • US
  • Canada
• Europe (Treatment Type, Route of Administration, Disease Type, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Route of Administration, Disease Type, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Route of Administration, Disease Type, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Route of Administration, Disease Type, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ono Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptive Biotechnologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Legend Biotech Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MorphoSys AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Secura Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations